Pentixapharm Announces Expansion of Supervisory Board with the Appointment
of Distinguished Endocrinologist Marcus Quinkler

EQS-News: Pentixapharm AG / Key word(s): Personnel
Pentixapharm Announces Expansion of Supervisory Board with the Appointment
of Distinguished Endocrinologist Marcus Quinkler

01.07.2024 / 13:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Pentixapharm Announces Expansion of Supervisory Board with the Appointment
of Distinguished Endocrinologist Marcus Quinkler

Würzburg and Berlin, Germany July 1st, 2024 - Pentixapharm AG, a
clinical-stage biotech company discovering and developing novel targeted
radiopharmaceuticals against a broad range of malignancies, announced today
that the General Shareholder Meeting of Pentixapharm resolved the
appointment of the distinguished endocrinologist Prof. Dr. med. Marcus
Quinkler to the Company's Supervisory Board. The assignment will become
effective with the registration of the split-off of Pentixapharm AG from
Eckert & Ziegler SE in the commercial register.

"We welcome Marcus Quinkler as a valuable addition to our Board. He is a
recognized expert among others in primary aldosteronism, the focus area of
our Phase III lead program PENTIXAFOR (PTF-302). He will also help
Pentixapharm to advance its ongoing clinical assessments of the Company's
novel, CXCR4-based radiopharmaceutical therapeutic and diagnostic programs."
explained Dr. Hakim Bouterfa, Founder and Chief Executive Officer of the
Pentixapharm Holding AG.

Marcus Quinkler is a specialist of internal medicine and endocrinology,
diabetology and andrology. Formerly at the endocrinology department at the
Charité-Universitätsmedizin, Campus Mitte, Berlin, currently leading a
specialized endocrine practice in Berlin, Dr. Quinkler has significantly
contributed to the field, serving as an adjunct professor at Charité.

His academic training includes a medical degree and doctorate from the Free
University of Berlin, a research fellowship at the University of Birmingham,
U.K., funded by the DFG, and a postdoctoral thesis at the Charité to qualify
as a professor. Dr. Quinkler has led significant clinical guideline
developments and held editorial roles in prominent journals. His accolades
include the Schoeller-Junkmann Prize and the Arthur-Jores Honorary Prize
from the German Society for Endocrinology (DGE). From 1996 to 2024, Dr.
Quinkler has authored over 270 peer-reviewed publications.

Dr. Marcus Quinkler added: "Pentixapharm's CXCR4-ligand technologies are
being evaluated not only in hematological indications but also for a range
of other applications beyond cancer. Notably, their advanced diagnostic
program in Primary Aldosteronism holds significant promise as a meaningful
alternative to the current gold standard, potentially improving patient
outcomes and enhancing cardiovascular health. I am pleased to join the Board
at this pivotal moment and support the Company in their future growth."

Dr. Quinkler will strengthen the Supervisory Board of Pentixapharm AG next
to Chairman Dr. Andreas Eckert, Jens Giltsch and Dr. Harald Hasselmann, who
also serves as CEO of Eckert & Ziegler SE.

About Pentixapharm AG

Pentixapharm is a radiopharmaceutical development company founded in 2019
with its headquarters in Würzburg, Germany. It is currently wholly owned by
the Eckert & Ziegler Group but bound to be spun-off to the Frankfort Stock
Exchange soon. Pentixapharm is committed to developing CXCR4 ligand-based
first-in-class radiopharmaceutical approaches with a clear commercial
pathway for diagnostic and therapeutic programs in a number of hematological
and solid cancers, as well as cardiovascular and endocrine diseases.

Pentixapharm's clinical program encompasses PENTIXATHER, am Yttrium-90 based
therapeutic against CNS lymphoma, and PENTIXAFOR, a Gallium-68 based
companion diagnostic. Clinical studies for both compounds have already
commenced in Europe, with a dose-finding study for PENTIXATHER and a Phase
III registration study for PENTIXAFOR. Additionally, PENTIXAFOR is being
developed as a diagnostic tool for primary aldosteronism, a significant
cause of hypertension. Pentixapharm aims to initiate an advanced clinical
trial in the United States in 2025.

For more information, please contact:

Eckert & Ziegler SE
Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10,
13125 Berlin, Germany
Tel.: +49 30 / 94 10 84-138
karolin.riehle@ezag.de, www.ezag.com

Pentixapharm AG
Phillip Eckert, Investor Relations
phillip.eckert@pentixapharm.com
Tel. +49 30 94 10 84 227
www.pentixapharm.com

Media Contact:
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
Tel. +49 211 529252 22


---------------------------------------------------------------------------

01.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

1936961 01.07.2024 CET/CEST